Research
Current Trials:
-Nontuberculous Mycobacterium Clinical Database & Biospecimen Bank
-Bronchiectasis Research Registry
-MAC 2v3-Multicenter randomized pragmatic clinical trial comparing two-versus three-antibiotic therapy for pulmonary Mycobacterium avium complex disease
-PARATEK-A Phase 2, double-Blind, Randomized, parallel-Group, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety, and Tolerability of oral Omadacycline in Adult Subjects with Nontuberculous Mycobacterial (NTM) Pulmonary Disease Caused by Mycobacterium abscessus Complex (MABc)
-EBO-301-A Phase 2/3, Randomized, Double-blind, Placebo-controlled, Multicenter, prospective Study to Assess the Efficacy, Safety, and Pharmacokinetics of orally Administered Epetraborole in Patients with Treatment-refractory Mycobacterium avium Complex Lund Disease (MACrO2)
-RENOVION-A Phase 2a, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of ARINA-1 administered twice daily by nebulizer in adult participants with non-cystic fibrosis bronchiectasis (NCFBE) with excess mucus and cough
-ASPEN-A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects with Non-Cystic Fibrosis Bronchiectasis-
-ENCORE-A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects with newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium avium Complex (MAC)
-MAC-CLOFAZIMINE-001 Clofazimine in the treatment of pulmonary Mycobacterium avium complex (MAC) disease
-Post trial Access (PTA) Program for Brensocatib (WILLOW and ASPEN)
-Multiple Patient Program for Lamprene (clofazimine) for the treatment of Non-Tuberculous Mycobacterial (NTM) Infections
Completed trials:
-ARISE-A randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported outcome Instruments in Adult Subjects with Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lund Infection Caused by Mycobacterium avium Complex (MAC)
-WILLOW- A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Assess the Efficacy, Safety and Tolerability, and Pharmacokinetics of INS1007 Administered Once Daily for 24 Weeks in Subjects with Non-Cystic Fibrosis Bronchiectasis
-INS 212-A Randomized, Open-Label, Multicenter Study of Liposomal Amikacin for Inhalation (LAI) in Adult patients with Nontuberculous Mycobacterial (NTM) Lung Infections caused by Mycobacterium avium complex (AMC) that are refractory to treatment
-INS 312-An Open-Label Safety Extension Study to a Multicenter Study of Liposomal Amikacin for Inhalation (LAI) in Adult Patients with Nontuberculous Mycobacterial (NTM) Lung Infections caused by Mycobacterium avium complex (MAC) that are refractory to treatment